Sweden's Xintela Q4 income drops 62% yr/yr

Xintela AB

27/02/2026 06:08

Overview

Sweden-based biopharma's Q4 income fell to TSEK 415 from TSEK 1,090 yr/yr

Company's oncology unit collaborates with Memorial Sloan Kettering on cancer therapy

Company completed clinical study with XSTEM in difficult-to-heal leg ulcers

Outlook

Company did not provide specific guidance for future quarters or years

Result Drivers

COLLABORATION WITH MSK - Xintela's oncology subsidiary Targinta AB collaborates with Memorial Sloan Kettering for clinical development of integrin α10β1-targeted antibodies

RIGHTS ISSUE - Co raised approximately SEK 42 mln through rights issue and loan conversion

CLINICAL STUDY COMPLETION - Xintela completed clinical study with XSTEM in difficult-to-heal leg ulcers

Company press release: ID:nMFN3qZDWr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-SEK 0.02


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)